Adicet Bio Inc

Adicet Bio is advancing its lead candidate prula-cel in autoimmune diseases and expects to report updated phase I data in the third quarter of 2026. The company plans to begin a pivotal study in lupus nephritis in the second half of 2026, subject to regulatory clearance, and will provide additional clinical updates for systemic sclerosis and rheumatoid arthritis later that year. Adicet also expects to submit a regulatory filing for ADI-212, a gene-edited cell therapy for metastatic castration-resistant prostate cancer, in the third quarter of 2026 and begin phase I enrollment in the fourth quarter. Over the past 30 days, analysts have narrowed the 2026 loss per share estimate for Adicet from $8.61 to $6.76, while widening the 2027 loss estimate from $3.71 to $5.64. The stock has risen 9.2% year to date, compared with an 11.1% gain for the industry.